Seven Fleet Capital Management LP Makes New $917,000 Investment in Maze Therapeutics, Inc. $MAZE

Seven Fleet Capital Management LP bought a new stake in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 30,707 shares of the company’s stock, valued at approximately $917,000. Seven Fleet Capital Management LP owned approximately 0.06% of Maze Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Royal Bank of Canada lifted its stake in shares of Maze Therapeutics by 128.3% during the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after purchasing an additional 363 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in Maze Therapeutics in the fourth quarter worth about $39,000. Ameritas Investment Partners Inc. raised its holdings in Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after purchasing an additional 738 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of Maze Therapeutics in the 4th quarter valued at about $43,000. Finally, Russell Investments Group Ltd. raised its stake in shares of Maze Therapeutics by 947.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after acquiring an additional 1,725 shares in the last quarter.

Maze Therapeutics Stock Down 2.6%

NASDAQ:MAZE opened at $26.92 on Friday. The company has a debt-to-equity ratio of 0.11, a current ratio of 17.88 and a quick ratio of 17.88. The company’s fifty day moving average price is $27.36 and its 200-day moving average price is $34.05. Maze Therapeutics, Inc. has a 1-year low of $12.81 and a 1-year high of $53.65. The firm has a market capitalization of $1.49 billion, a P/E ratio of -10.64 and a beta of 2.14.

Maze Therapeutics (NASDAQ:MAZE) last posted its earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The company had revenue of $20.00 million for the quarter. As a group, equities research analysts anticipate that Maze Therapeutics, Inc. will post -2.73 EPS for the current year.

Insider Buying and Selling at Maze Therapeutics

In related news, CEO Jason V. Coloma sold 34,501 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $29.98, for a total transaction of $1,034,339.98. Following the sale, the chief executive officer directly owned 23,337 shares of the company’s stock, valued at $699,643.26. This trade represents a 59.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $27.34, for a total value of $205,050.00. Following the sale, the insider directly owned 26,250 shares in the company, valued at approximately $717,675. This trade represents a 22.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 141,470 shares of company stock worth $3,902,714. Insiders own 5.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on MAZE. Truist Financial decreased their price objective on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating for the company in a report on Tuesday, April 14th. Wall Street Zen raised shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $66.00.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.